Antibe Therapeutics Announces No Material Change

TORONTO–(BUSINESS WIRE)–Antibe Therapeutics Inc. (“Antibe” or the “Company”) (TSXV: ATE, OTCQB:
ATBPF) wishes to advise that it is not aware of any undisclosed material
change in the Company’s activities that would account for recent market
activity. As previously disclosed in its February 26th, 2018
press release, the Company anticipates being in a position to report
top-line results of the Phase 2b clinical trial of its lead drug,
ATB-346, during the week of March 19th, 2018.

About Antibe Therapeutics Inc.
Antibe develops safer
medicines for pain and inflammation. Antibe’s technology involves
linking a hydrogen sulfide-releasing molecule to an existing drug to
produce a patented, improved medicine. Antibe’s lead drug ATB-346
targets the global need for a safer, non-addictive drug for chronic pain
and inflammation. ATB-352, the second drug in Antibe’s pipeline, targets
the urgent global need for a non-addictive analgesic for treating severe
acute pain, while ATB-340 is a GI-safe derivative of aspirin.

Antibe’s subsidiary, Citagenix Inc. (“Citagenix”), is a leader in the
sales and marketing of tissue regenerative products servicing the
orthopedic and dental marketplaces. Since its inception in 1997,
Citagenix has become an important source of knowledge and experience for
bone regeneration in the Canadian medical device industry. Citagenix is
active in 15 countries, operating in Canada through its direct sales
teams, and internationally via a network of distributor partnerships.

Forward Looking Information

This news release includes certain forward-looking statements, which may
include, but are not limited to, the proposed licensing and development
of drugs and medical devices. Any statements contained herein that are
not statements of historical facts may be deemed to be forward-looking,
including those identified by the expressions “will”, “anticipate”,
“believe”, “plan”, “estimate”, “expect”, “intend”, “propose” and similar
expressions. Forward-looking statements involve known and unknown risks
and uncertainties that could cause actual results, performance, or
achievements to differ materially from those expressed or implied in
this news release. Factors that could cause actual results to differ
materially from those anticipated in this news release include, but are
not limited to, the Company’s inability to secure additional financing
and licensing arrangements on reasonable terms, or at all, its inability
to execute its business strategy and successfully compete in the market,
and risks associated with drug and medical device development generally.
Antibe Therapeutics Inc. assumes no obligation to update the
forward-looking statements or to update the reasons why actual results
could differ from those reflected in the forward-looking statements
except as required by applicable law.


Antibe Therapeutics Inc.
Dan Legault, (416) 473 4095
Executive Officer